---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-219091"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T04:57:00.680615+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Ginkgo files updated pro forma financials for Zymergen acquisition; pro forma net loss $2.4B

## Summary
- Pro forma combined revenue $487.8M for FY 2022; Ginkgo standalone $477.7M, Zymergen $10.1M.
- Pro forma net loss attributable to Ginkgo stockholders $2.405B; diluted EPS loss $1.37.
- Adjustments include $8.1M net reduction in operating expenses from fair value and compensation changes.
- Weighted average shares outstanding increased to 1.76B from 1.68B due to Merger consideration shares.

## SEC filing metadata
- accession: 0001193125-23-219091
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000119312523219091/0001193125-23-219091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000119312523219091/d506467d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-219091
- JSON: https://secwatch.observer/filing/0001193125-23-219091.json
- Plain text: https://secwatch.observer/filing/0001193125-23-219091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.